Pharmaceutical composition for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis, comprising adenosine derivatives

Abstract

An oral agent for preventing or treating liver disease is provided. The oral agent includes a compound represented by formula 1 below or a pharmaceutically acceptable salt of the compound as an active ingredient:where A is S, R is a linear or branched C1-C5 alkyl which is non-substituted or is independently or selectively substituted with one or more C6-C10 aryl groups, a benzyl which is non-substituted or is independently or selectively substituted with halogen or one or more linear or branched C1-C4 alkoxy groups, or a hydroxycarbonyl-substituted benzyl, and Y is H or a halogen atom.

What is claimed is: 
     
         1 . A method of treating a liver disease in a subject in need thereof, comprising:
 administering an oral agent comprising a compound represented by formula 1 below or a pharmaceutically acceptable salt of the compound to the subject:   
       
         
           
           
               
               
           
         
         where A is S, R is a linear or branched C 1 -C 5  alkyl which is non-substituted or is substituted with one or more C 6 -C 10  aryl groups, a benzyl which is non-substituted or is substituted with halogen or one or more linear or branched C 1 -C 4  alkoxy groups, or a hydroxycarbonyl-substituted benzyl, and Y is H or a halogen atom. 
       
     
     
         2 . The method of  claim 1 , wherein the oral agent further comprises a vehicle which comprises one or more of methyl cellulose (MC), dimethyl sulfoxide (DMSO), polyethylene glycol (PEG), and distilled water. 
     
     
         3 . The method of  claim 1 , wherein the compound represented by formula 1 or the pharmaceutically acceptable salt of the compound is filled in a powder state in a capsule. 
     
     
         4 . The method of  claim 1 , wherein the liver disease comprises one or more of NASH or NAFLD, liver fibrosis, and liver cirrhosis. 
     
     
         5 . The method of  claim 1 , wherein the formula 1 is a compound represented by formula A below: